|Title||Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.|
|Publication Type||Journal Article|
|Year of Publication||2018|
|Authors||Ranganathan U, Kaunzner U, Foster S, Vartanian T, Perumal JS|
|Date Published||2018 04|
|Keywords||Alemtuzumab, Antibodies, Monoclonal, Humans, Multiple Sclerosis, Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia, Treatment Outcome|
BACKGROUND: Alemtuzumab is a monoclonal antibody approved for relapsing-remitting multiple sclerosis (RRMS). Although Immune thrombocytopenia (ITP) has been reported as a secondary autoimmune phenomenon following alemtuzumab infusion, immediate thrombocytopenia during the infusion has not been reported.
OBJECTIVE: We report transient, reversible, self-limiting acute-onset thrombocytopenia during the first course with alemtuzumab.
RESULTS AND CONCLUSION: In total, 3 of 22 paitents developed mild self-limited bruising associated with a drop in platelet count from their baseline during the intial 5-day course of alemtuzumab. Upon chart review, all 22 patients who received alemtuzumab developed an immediate mostly asymptomatic drop in platelet count which returned to normal within 2 months post-infusion.
|Alternate Journal||Mult. Scler.|